Support for Women with HER2+ Breast Cancer
Genentech, USA, Inc.
FREE - On the App Store (iPhone® Only)
KADCYLA is made to find HER2-positive cells and attach to them. It tells the cells to stop growing and tells the body’s immune system to destroy them.
KADCYLA also goes inside the cell to keep fighting from the inside.
KADCYLA releases the chemotherapy inside the cell.
The chemotherapy goes to work inside the cell, causing the cell to die.
HER2-positive or HER2+
Breast cancer cells that have too many HER2 receptors.
Adjuvant treatment is additional treatment for early breast cancer that is given just after, and complementary to, the main treatment (usually surgery). For HER2+ breast cancer, this may include radiation therapy, chemotherapy, hormonal therapy, and/or targeted therapy.
A type of protein that is found on the surface of cells in everyone. This protein tells cells to grow and divide. Too much HER2 is called “HER2 overexpression.”
Metastatic breast cancer
Breast cancer that has spread outside the breast to other parts of the body, such as the lungs, liver, or bones.
Monoclonal antibody cancer therapy
A molecule that is made to target specific cancer cells and may affect normal cells.
A type of cancer treatment that kills cells that grow and divide rapidly. This can include cancer cells or normal cells.
Intravenous (IV) infusion
Getting medicine through a needle directly into a vein. Some medicines, such as KADCYLA, can only be given by IV infusion.
Your body’s natural defense against infections and disease.
KADCYLA is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.
KADCYLA (ado-trastuzumab emtansine)
Contact your doctor right away if you experience symptoms associated with these side effects.
Not all people have serious side effects; however, side effects with KADCYLA treatment are common. It is important to know what side effects may happen and what symptoms you should watch for.
You must have a HER2 test to determine if your cancer is HER2-positive before taking KADCYLA, because benefit has been shown only in patients whose tumors are HER2-positive.
The most common severe side effects of KADCYLA are:
The most common side effects seen in people taking KADCYLA were:
You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-25551-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-10881-800-FDA-1088.
Please see KADCYLA full Prescribing Information, including Most Important Safety Information, for additional Important Safety Information.